- HC Wainwright initiated coverage of Lyell Immunopharma Inc (NASDAQ:LYEL) with a Buy rating and a price target of $12 per share.
- Lyell leverages two ex vivo epigenetic reprogramming technologies, Gen-R and Epi-R, which are designed to generate T-cell populations that are more effective and resilient.
- The analyst believes the technologies position Lyell as a solid tumor cell therapy leader.
- LYL845 is a tumor-infiltrating lymphocyte (TIL) therapy designed to incorporate the Epi-R technology.
- HC Wainwright says LYL845 design can potentially help overcome challenges associated with competing TIL products, including limited efficacy due to poor enrichment of tumor-reactive T cells, poor quality and growth potential of expanded T cells, and failure to maintain polyclonality of TILs during production.
- Earlier this month, the FDA cleared the Investigational New Drug application to initiate a Phase 1 trial for LYL845.
- Patient screening for the Phase 1 trial is set to begin over the coming months, and initial clinical data is expected in 2024.
- Price Action: LYEL shares are up 3.98% at $6.80 on the last check Monday.
ŌURA and Talkspace Launch First-Of-Its-Kind Holistic Sleep Partnership
Powered by leading smart ring's new Share Report feature to provide insights for more personalized care
Today ŌURA, the company behind the smart ring that delivers personalized health data, insights, and
